Latest News

Credit: Sebastian Kaulitzki | stock.adobe.com
FDA Grants Accelerated Approval to AbbVie’s Emrelis for the Treatment of NSCLC Based on Phase II Trial Results

May 15th 2025

In the Phase II LUMINOSITY study, Emrelis (telisotuzumab vedotin-tllv), a first-in-class c-Met-directed antibody-drug conjugate, demonstrated an overall response rate of 35%.

A Closer Look at NIH Grant Terminations
A Closer Look at NIH Grant Terminations

May 15th 2025

Credit: MohammedElAmine | stock.adobe.com
KEYNOTE-B96 Trial Shows Keytruda is First Immunotherapy to Improve Overall Survival in Platinum-Resistant Ovarian Cancer

May 15th 2025

3 Perspectives on Medical Research Funding Cuts
3 Perspectives on Medical Research Funding Cuts

May 14th 2025

Credit: Juan Gärtner | stock.adobe.com
iTeos and GSK Halt TIGIT Antibody Belrestotug Development After Phase II Trials Miss Efficacy Marks in NSCLC and HNSCC

May 14th 2025

Applied Clinical Trials April 2025

Check out the latest features and columns!

Check out the latest features and columns!

Conference Coverage

View All
© Egor - © Egor - stock.adobe.com
Notable Discussions from SCOPE 2025: Aiming to Calculate, Accommodate, and Innovate for Enhanced Drug Development

March 11th 2025

Set the Course for a More Engaging & Productive Patient & Clinical Trial Site Journey
Set the Course for a More Engaging & Productive Patient & Clinical Trial Site Journey

February 26th 2025

SCOPE Summit 2025: Shakthi Kumar Talks Real-World Data Use in Clinical Development
SCOPE Summit 2025: Shakthi Kumar Talks Real-World Data Use in Clinical Development

February 24th 2025

SCOPE Summit 2025: Graham Clark on Ensuring Data Consitency Amid the Rise of Real-World Evidence
SCOPE Summit 2025: Graham Clark on Ensuring Data Consitency Amid the Rise of Real-World Evidence

February 21st 2025

Latest Videos
Podcasts

All News

© 2025 MJH Life Sciences

All rights reserved.